All News

RheumNow Podcast square

ACR Convergence Preview (11.10.2023)

Jack Cush, MD

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 

Read Article
RheumNow Podcast square

Late Should Not Be Less (11.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
microbiome,blue

Gut Microbiome Differences Antedate JIA Development

Jack Cush, MD

Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.

Read Article
JIA_0.jpg

Monoarticular JIA - a Distinct Clinical Entity

Jack Cush, MD

Monoarticular Juvenile Idiopathic Arthritis (monoJIA) is typically classified under oligoarticular JIA, but a recent study suggests it is a separate entity.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
pregnancy,birth,preterm,baby

Antenatal Corticosteroids and Serious Infection in Offspring

Jack Cush, MD

A claims data study shows that maternal use of antenatal corticosteroids may be associated with an increased risk of serious infection in the offspring's first 12 months. 

Read Article
CSS Storm Cytokine

EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

Jack Cush, MD

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.

Read Article
JIA.oligoarticular.jpg

MMWR: Arthritis Among Children and Adolescents

Jack Cush, MD

The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.

Read Article
Things for me to take back to the clinic in looking after JIA patients, Sadun R, #ACR23 @RheumNow https://t.co/YkiP4GZG19
Dr. Antoni Chan  ( View Tweet)
New clinical skill to use in the clinic. Auscultate at the TMJ for crepitus and measure the maximal incisal opening in JIA, Sadun R, #ACR23 @RheumNow https://t.co/8koZRCZYoP
Dr. Antoni Chan  ( View Tweet)
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions. https://t.co/MRFwrCXIlQ https://t.co/Su3nMs4CNW

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG

Links:

Dr. John Cush RheumNow ( View Tweet)
Anifrolumab was studied in 7 adolescents w/ resistant #DLE (discoid); given 6 monthly IV doses. All had signif decreases in skin CLASI-A scores (72%) at 1 month (P =.01), sustained at 6-mo F/U. SLEDAI-2K score also decr by 7 pts; 1 had HSV-1 reactivation https://t.co/Nc0IN1Rsao https://t.co/XeAB99YZMF

Links:

Dr. John Cush RheumNow ( View Tweet)
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/6ZxIcHbUEd https://t.co/Cx0kbn7JU2

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR: Arthritis Among Children and Adolescents The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. https://t.co/pQnB3zV7sw https://t.co/nrLZ8Uazgh

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA's CHMP adopted a positive opinion for 1st tocilizumab biosimilar, Tyenne® (from Fresenius Kab), for Rx of RA, systemic JIA, poly JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome. No decision yet on IL6 biosimilar in USA https://t.co/w00yGfm3Vv https://t.co/UzxPvBf1nG

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×